Jove
Visualize
Contact Us

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

12
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
12
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.3K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.3K
Integrated Healthcare System01:20

Integrated Healthcare System

1.9K
An integrated healthcare system (IHS) is a set of organizations that provides for or arranges to provide coordinated and continuous service to a defined population. The IHS takes responsibility for that particular population's health status and outcome, both clinically and fiscally. An integrated healthcare system is a well-organized, well-coordinated, and collaborative network. The integrated delivery system is a network that connects different healthcare providers to deliver organized,...
1.9K
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

15
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
15
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

13
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
13
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

23
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
23

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Pressure Inelastic Neutron Spectroscopy: Experimental Validation of Machine-Learned Interatomic Potential Energy Landscapes.

The journal of physical chemistry letters·2026
Same author

On Time Saves Lives: Survey Insights and Position Statement from the American Epilepsy Society on Barriers to Antiseizure Medication Access.

Epilepsy currents·2026
Same author

Biallelic variants in RNU2-2 cause a remarkably frequent developmental and epileptic encephalopathy.

Nature genetics·2026
Same author

Biallelic GLTP mutations cause nonsyndromic epidermal differentiation disorder via disrupted epidermal glucosylceramide transport.

The Journal of clinical investigation·2026
Same author

Lobular Breast Carcinoma Presenting as an Endometrial Polyp Metastasis: A Report of a Novel Asynchronous Presentation.

Cureus·2025
Same author

The clinical and molecular spectrum of the KDM6B-related neurodevelopmental disorder.

American journal of human genetics·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Oct 12, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.9K

Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System.

Bharati Bhardwaja1,2, Shilpa Klocke3,4, Ekim Ekinci3

  • 1Clinical Pharmacy Specialist, Kaiser Permanente Colorado, Denver, CO, USA. bharati.bhardwaja@kp.org.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|November 24, 2021
PubMed
Summary

Kaiser Permanente Colorado successfully switched over 90% of patients to biosimilars, demonstrating a viable model for healthcare systems. This approach offers significant cost savings for biologics, benefiting both payors and patients.

More Related Videos

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

1.3K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.8K

Related Experiment Videos

Last Updated: Oct 12, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.9K
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

1.3K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.8K

Area of Science:

  • Pharmacoeconomics
  • Health Services Research
  • Drug Development

Background:

  • Biologics offer effective treatments but are costly for healthcare systems and patients.
  • Biosimilars, approved as highly similar to originator biologics, present an opportunity for significant cost reduction.
  • Healthcare organizations are exploring strategies for transitioning patients from biologics to biosimilars.

Purpose of the Study:

  • To describe a model for implementing biosimilar switches within a healthcare system.
  • To share practical learnings from Kaiser Permanente Colorado's (KPCO) experience with biosimilar adoption.
  • To provide a framework for other healthcare systems considering biosimilar transitions.

Main Methods:

  • KPCO initiated biosimilar switches starting with filgrastim in 2016.
  • The study details the process and outcomes of multiple biosimilar switches.
  • Patient transition rates were tracked for various originator biologics and their biosimilars.

Main Results:

  • KPCO achieved high patient switch rates: 91.8% for infliximab, 99.8% for rituximab.
  • 100% of patients were switched to biosimilars for filgrastim, trastuzumab, and bevacizumab.
  • The experience highlights successful implementation of biosimilar transition strategies.

Conclusions:

  • The KPCO biosimilar switch model demonstrates high success rates and feasibility.
  • Implementing biosimilar switches can lead to substantial cost savings.
  • The findings offer valuable insights for healthcare systems aiming to adopt biosimilars.